SCHEMBL10100350

SCHEMBL10100350

Nc1ncnn2c([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)cc(C(=O)O)c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HIF1A Q16665 3/20 0.41
▸ GAPDH P04406 2/20 0.37
▸ ADORA3 P0DMS8 2/20 0.37
▸ ADORA2A P29274 2/20 0.37
▸ DOT1L Q8TEK3 2/20 0.37
▸ DPP4 P27487 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ SLC28A1 O00337 1/20 0.37
▸ MAP3K7 O43318 1/20 0.37
▸ SLC28A2 O43868 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ ADORA2B P29275 1/20 0.37
▸ ADORA1 P30542 1/20 0.37
▸ STAT6 P42226 1/20 0.37
▸ PI4KA P42356 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ PI4K2B Q8TCG2 1/20 0.37
▸ SLC29A1 Q99808 1/20 0.37
▸ PI4K2A Q9BTU6 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10101575 0.91 CSNK2A2 (0.34) HIF1AGAPDHADORA3ADORA2ADOT1L
SCHEMBL13519789 0.91 LGALS3 (0.35) HIF1AGAPDHADORA3ADORA2ADOT1L
SCHEMBL10101576 0.83 CSNK2A2 (0.34) ACVRL1
SCHEMBL10101513 0.83 CSNK2A2 (0.34) ACVRL1
SCHEMBL10101578 0.82 KDM4E (0.36) HIF1AGAPDHADORA3ADORA2ADOT1L
SCHEMBL13519808 0.79 ADORA2A (0.41) ADORA2AACVRL1
SCHEMBL647116 0.79 ADORA2A (0.41) ADORA2AACVRL1
SCHEMBL13519756 0.78 ACVRL1 (0.36) ACVRL1
SCHEMBL10101583 0.78 NPC1 (0.40) HIF1AGAPDHADORA3ADORA2ADOT1L
SCHEMBL14642542 0.78 CSNK2A2 (0.36) ACVRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2114980-B1 ANTIVIRAL NUCLEOSIDE ANALOGS BIOCRYST PHARM INC (US) 2012-06-27 — — EP disclosed
Send feedback